Search clinical trials for: Placebo (NNC6019-0001)

Total 54521 results

Novo Nordisk A/S

Active, not recruiting

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Spain, Portugal, Canada, Czechia, France, Germany, Italy, Japan
Novo Nordisk A/S

Recruiting

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People

Healthy Volunteers | Cardiometabolic Diseases

Netherlands
Novo Nordisk A/S

Recruiting

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
Alaunos Therapeutics

Completed

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

Melanoma

United States
Gillette Children's Specialty Healthcare
Lite Run Inc.

Completed

Post-operative Lite Run Study

Cerebral Palsy | Neurologic Disorder | Spina Bifida | Chromosome Abnormality

United States
Novo Nordisk A/S

Completed

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Inflammation | Healthy | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients (paradigm™ 2)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Germany, Macedonia, The Former Yugoslav Republic of, United Kingdom, Italy, Malaysia, Hungary, Thailand, France, Russian Federation, Turkey, Japan, South Africa, Canada
Janssen Research & Development, LLC

Completed

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Inflammation | Crohn's Disease

Belgium, France, Israel, Hungary, Russian Federation, Poland, Canada, United States
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Healthy Volunteers (Diabetes Mellitus, Type 2)

Germany, Denmark
Creabilis SA
LCG Bioscience

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

Safety
Alaunos Therapeutics

Completed

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Melanoma

United States
Alaunos Therapeutics

Completed

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma

United States
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

Non-alcoholic Steatohepatitis

Japan
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

United Kingdom, Romania, Poland, Denmark, Czech Republic, Hungary
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
Novo Nordisk A/S

Completed

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Chiesi Farmaceutici S.p.A.

Completed

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Novo Nordisk A/S

Completed

Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

United Kingdom, Italy, Poland, Portugal, Spain, Germany, Czech Republic, Romania
Viramal Limited

Completed

Exploratory Study on Two Different Doses of VML-0001 on the Effects on Vaginal pH in Healthy Post-Menopausal Women

Vaginal Atrophy

United States
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Novo Nordisk A/S

Recruiting

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

Healthy Volunteers

Austria
Novo Nordisk A/S

Completed

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (paradigm™5)

Congenital Bleeding Disorder | Haemophilia B

United States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
Oryzon Genomics S.A.
Alzheimer's Drug Discovery Foundation

Completed

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease (ETHERAL-US)

Mild to Moderate Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Inflammation | Healthy | Rheumatoid Arthritis | Systemic Lupus Erythematosus

Netherlands
Novo Nordisk A/S

Withdrawn

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

United States
ReAlta Life Sciences, Inc.
Premier Research Group plc

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia (STAR)

Hypoxic-Ischemic Encephalopathy

United States
Celgene

Terminated

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

Crohn Disease

United States, Korea, Republic of, Netherlands, Spain, Belgium, Denmark, Australia, Austria, Russian Federation, United Kingdom, Croatia, Canada, Italy, Hungary, Israel, Portugal, Serbia, Poland, Germany, France, Czechia, Greece, Sl... and more
Celgene

Completed

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

Crohn Disease

United States, Australia, Canada, Slovakia, Hungary
Novo Nordisk A/S

Completed

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Russian Federation, Germany
Janssen Research & Development, LLC

Completed

Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Ukraine
Novo Nordisk A/S

Terminated

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

Serbia, Hungary, Poland, United States
HemaQuest Pharmaceuticals Inc.

Completed

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Sickle Cell Disease

United States, Jamaica
IVIEW Therapeutics Inc.

Not yet recruiting

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Novo Nordisk A/S

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Korea, Republic of, India, Australia, Canada, Japan, South Africa
ReAlta Life Sciences, Inc.

Completed

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

Healthy Volunteer

Canada
Dalhousie University
Canadian Institutes of Health Research (CIHR); NewLink Genetics Corporation

Completed

Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (VSVΔG-ZEBOV)

Ebola Viruses
University Medical Center Groningen
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161)

NHL | DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
Avidity Biosciences, Inc.

Not yet recruiting

Global Study of Del-desiran for the Treatment of DM1 (HARBOR)

Myotonic Dystrophy | Myotonic Disorders | Myotonia | Myotonic Dystrophy Type 1 (DM1) | Myotonic Dystrophy 1 | Myotonic Muscular Dystrophy | DM1 | Dystrophy Myotonic | Steinert Disease | Steinert
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.

Rare Diseases

Japan
Novo Nordisk A/S

Terminated

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Withdrawn

Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers

Obesity | Metabolism and Nutrition Disorder
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
Alaunos Therapeutics

Completed

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

Metastatic Breast Cancer

United States
Ablynx, a Sanofi company

Completed

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, Turkey, United Kingdom
National Drug Clinical Trial Institute of the Second...
Therorna

Recruiting

A Study to Evealuate Safety and Immunogenicity of TI-0010 SARS-CoV-2 Vaccine in Healthy Adults

COVID-19 | COVID-19 Immunisation

China

Search clinical trials for: Placebo (NNC6019-0001)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations